Rates of Serious Infections and Malignancies Among Patients with Rheumatoid Arthritis Receiving Either Tumor Necrosis Factor Inhibitor or Rituximab Therapy.

CONCLUSION: Our results provide some reassurance of the safety of biologic treatments in the treatment of RA.
PMID: 25593230 [PubMed - as supplied by publisher]

Source: J Rheumatol - January 15, 2015 Category: Rheumatology Authors: Aaltonen KJ, Joensuu JT, Virkki L, Sokka T, Aronen P, Relas H, Valleala H, Rantalaiho V, Pirilä L, Puolakka K, Uusitalo T, Blom M, Konttinen YT, Nordström D Tags: J Rheumatol Source Type: research